Divestment21 Sept 2026, 02:58 pm
Thyrocare Sells Radiology Arm NHL for ₹1414 Cr
AI Summary
Thyrocare Technologies Limited announced the sale of its entire shareholding in its wholly-owned subsidiary, Nueclear Healthcare Limited (NHL), to Trovera Healthcare Private Limited for approximately ₹1,414 crore. The divestment includes 1.11 crore equity shares, representing 100% of NHL. The consideration comprises Compulsorily Convertible Preference Shares (CCPS) in Trovera valued at ₹595 crore and cash of approximately ₹819 crore. This strategic move allows Thyrocare to focus on its core pathology business. The transaction is subject to shareholder and regulatory approvals.
Key Highlights
- Thyrocare to sell entire stake in subsidiary NHL for ₹1414 crore.
- Divestment includes 100% equity in radiology business subsidiary.
- Consideration includes CCPS in buyer and cash component.
- Company aims to focus on its core pathology business.
- Transaction subject to shareholder and regulatory approvals.
Price Impact
More from THYROCARE